Article Text

Natriuretic Peptides as Biomarkers in Heart Failure
  1. James L. Januzzi Jr, MD
  1. From the Cardiology Division, Massachusetts General Hospital, Boston, MA.
  1. Received March 22, 2013.
  2. Accepted for publication March 27, 2013.
  3. Reprints: James L. Januzzi, Jr, MD, Cardiology Division, Massachusetts General Hospital, Yawkey 5984, 55 Fruit St, Boston, MA 02114. E-mail: jjanuzzi{at}
  4. Presented at Experimental Biology 2013.
  5. This symposium was supported in part by a grant from the National Center for Research Resources (R13 RR023236). Dr. Januzzi is supported in part by the Roman W. Desanctis Endowed Distinguished Clinical Scholar Fund. He also has received grant support from Roche Diagnostics, Siemens AG, BG Medicine, Thermo Fisher, and Critical Diagnostics.


Following the initial discovery of a natriuretic and diuretic peptide factor present in atrial myocardial tissue homogenates, subsequent elucidation of the natriuretic peptide (NP) family has led to substantial advances in the understanding of the autocrine, paracrine, and endocrine regulation of the cardiovascular system. Furthermore, with the development of assays for the measurement of the NPs, these important biomarkers have gone from being regarded as biological mediators of the cardiovascular system to now represent important clinical tools for the diagnostic and prognostic evaluation of patients with heart failure and may have potential as a therapeutic target in this setting as well. An historical perspective on the NPs from bench to bedside translation will be discussed.

Key Words
  • natriuretic peptides
  • biology
  • diagnosis
  • prognosis
  • therapy

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.